MiNA Therapeutics

MiNA Therapeutics: Leader in a new class of RNA medicines - RNA activation (RNAa) therapeutics platform capable of upregulating any target gene to boost cells' protein production. Leveraging validated lipid nanoparticle delivery technology (exclusive license with BioNTech), MiNA is rapidly building out an internal pipeline initially focused on immuno-oncology and genetic rare diseases with 10 clinical assets expected by 2025. Lead program MTL-CEPBA is the first RNAa therapy to achieve clinical POC (randomized Ph2 study in combo with sorafenib in 2L HCC has 4Q23 readout, potential accelerated approval 2024, 3Q22 Ph1b readout in solid tumors with MTL-CEBPA+Pembro). Second RNAa candidate MTL-STING reactivates innate immune responses (AACR 2022 presentation, 1Q23 IND filing). Genetic rare disease portfolio with in vivo POC in 2022 for loss-of-function diseases and first IND in 2023. Raised $30M Series A lead by aMoon (Sep 2020). $1.5B+ partnerships with Eli Lilly, Servier, AstraZeneca; $25M upfront plus subsequent $16M investment from recent Lilly deal.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology, Oncology, Rare Disease
Investment Participation
Series A
Market Cap
Therapeutic Modalities
Platform Technology
84 Wood Lane
London, England W12 0BZ
United Kingdom

Company Participants at Solebury Trout 1x1 Management Access Event 2022

  • Robert Habib, Chief Executive Officer
  • Robin Wright, CFO